TL;DR
This study reveals that elevated uric acid (UA) levels in adults without diabetes are associated with mortality risks comparable to those seen in individuals with diabetes. This suggests that hyperuricemia might serve as an important indicator for managing cardiovascular risk factors in a broader population, not just those with diagnosed diabetes.
What Problem Does This Paper Address?
The paper addresses the question of whether hyperuricemia, a condition characterized by high levels of uric acid in the blood, is an independent risk factor for mortality, particularly cardiovascular disease (CVD), or if it's merely a marker associated with other conditions like diabetes. While diabetes is a well-established risk factor for increased mortality, the role of asymptomatic hyperuricemia in individuals without diabetes, especially when compared to diabetic individuals, has been less clear. The study aims to disentangle these associations by comparing mortality risks across different uric acid levels in both diabetic and non-diabetic populations, focusing on individuals without pre-existing coronary heart disease or chronic kidney disease.
Methods
The researchers utilized data from the National Health and Nutrition Examination Survey (NHANES) from 1999-2010, linked with mortality data up to December 2011. They employed Cox proportional hazards regression models to analyze the association between various uric acid (UA) levels and mortality outcomes (all-cause, CVD, and cancer). To facilitate comparisons, they established a reference group of non-diabetes participants with UA levels below 7 mg/dL. The analysis adjusted for several covariates including age, sex, race/ethnicity, body mass index (BMI), high-density lipoprotein cholesterol (HDL-C), systolic blood pressure (SBP), creatinine, and smoking status.
Datasets
The study used data from the National Health and Nutrition Examination Survey (NHANES) from 1999-2010, which includes a large, nationally representative sample of the U.S. population. This dataset was linked with the National Death Index (NDI) mortality data through December 2011 to ascertain mortality outcomes. The total number of participants included in the analysis was 29,226.
Key Insights and Ideas
- Hyperuricemia as a comparable risk factor: The most striking insight is that non-diabetes adults with elevated UA levels (≥7 mg/dL) exhibit all-cause and CVD mortality risks that are similar to those of diabetes adults with lower UA levels (<7 mg/dL). This suggests that hyperuricemia, in the absence of diabetes, might carry a significant mortality burden that warrants clinical attention.
- U-shaped association in non-diabetics: For non-diabetes adults, higher UA levels were associated with increasing risks of all-cause and CVD mortality, indicating a dose-response relationship.
- Diabetes and UA interaction: The study highlights the interplay between diabetes and UA levels. While diabetes itself is a risk factor, high UA levels in non-diabetics can elevate their risk to a level comparable to that of diabetics with lower UA.
- Focus on multifaceted risk management: The findings imply that managing cardiovascular risk factors in individuals with hyperuricemia, even without diabetes, should be as comprehensive as it is for diabetic patients. This suggests a need to look beyond just UA-lowering therapies and consider broader lifestyle and risk factor management.
Key Results
- Over a median follow-up of 6.6 years, 2069 participants died, with 495 from CVD and 520 from cancers.
- In non-diabetes adults, all-cause and CVD mortality risks significantly increased with higher UA levels (p-for-trend = 0.037 and 0.058, respectively) when UA was ≥5 mg/dL.
- For participants with diabetes, the lowest all-cause mortality risk was observed at a UA level of 5-7 mg/dL.
- Crucially, non-diabetes participants with UA levels of ≥7 mg/dL had an all-cause mortality risk equivalent to that of diabetes adults with UA levels <7 mg/dL (hazard ratio = 1.44 vs. 1.57, p = 0.49).
- A similar trend was observed for CVD mortality risk, with non-diabetes adults (UA ≥7 mg/dL) showing a hazard ratio of 1.80 compared to 2.06 for diabetes adults (UA <7 mg/dL), with p = 0.56.
- Cancer mortality risk did not show significant differences across UA levels or between diabetic and non-diabetic groups.
Limitations and Future Work
The authors acknowledge several limitations:
- Cross-sectional data for UA: The study used baseline UA levels, and changes in UA over the follow-up period were not considered, limiting the ability to definitively establish causality.
- Small sample size in high UA diabetic group: The number of participants with diabetes and UA levels ≥9 mg/dL was small, which could bias the mortality analyses in this specific subgroup.
- Glycemic control data: Glycated hemoglobin (HbA1c) data was not available for all participants, preventing the adjustment for glycemic control, which is a known factor influencing mortality in diabetes.
Future work suggested includes:
- Stricter clinical trials: The authors propose more rigorous clinical trials to investigate the effects of comprehensive cardiovascular risk factor management in hyperuricemic adults with lower baseline risk.
- Replication and further studies: The findings warrant further investigation and replication in diverse populations to confirm the role of hyperuricemia as a significant mortality indicator.
Summary updated